Peng J, Liang T, Chen C, et al. - In this retrospective study involving 26 consecutive children (37 eyes), mean gestational age was 34.5 ± 5.1 weeks and birth weight was 2,328.1 ± 1,083.9 g, with vascularly active total retinal detachments in one or both eyes, researchers characterized the surgical procedures, outcomes, and complications of a novel technique of subretinal injection of ranibizumab (SRR). Between September 2012 and September 2018, participants treated with SRR (0.25 mg/ 0.025 ml) as primary treatment were involved. The authors discovered that SRR in vascularly active advanced pediatric vasoproliferative disorders with total retinal detachments is effective and promising in this very limited study. However, more extensive controlled trials will be required to validate its safety and effectiveness. Local subconjunctival hemorrhage and localized wound leakage of subretinal fluid were reported adverse events in this analysis.